We work with a network of regional distributors to enable greater access to our portfolio of medicines in low- and middle-income countries. We also work with voluntary licensees, the Medicines Patent Pool and other stakeholders to expand access to our medicines around the world.
Regional Business Partners
Regional business partners serve as our on-the-ground interface with local governments, medical organizations, healthcare professionals and other stakeholders. In addition to delivering Gilead's HIV, viral hepatitis, COVID-19 and other treatments, our partners are instrumental in registering medicines with regulatory authorities and assisting with medical and clinical education.
Regional Business Partners
Voluntary Licensees
Generic drug manufacturers in India, China, South Africa, Egypt and Pakistan play a major role in expanding access to our HIV, viral hepatitis and COVID-19 medicines in low- and middle-income countries. Each year, through our voluntary license program, tens of millions of treatments are made available for HIV treatment and pre-exposure prophylaxis (PrEP), viral hepatitis B and C, and COVID-19.
HIV and Hepatitis B Voluntary Licensees
Hepatitis C Voluntary Licensees
COVID-19 Voluntary Licensees
Details of Licensing Agreements – Including Countries
Medicines Patent Pool
In 2011, Gilead was the first pharmaceutical company to join the Medicines Patent Pool (MPP) to expand access to its medicines through the sharing of drug patents. The MPP was established by UNITAID, a Geneva-based global health organization that works to make high-quality, life-saving treatments and diagnostics more affordable in low-income countries. Learn more about the Gilead-MPP license for HIV and hepatitis B medicines.